← Back to Search

18F-FMISO Breath Hold PET/CT for Non-Small Cell Lung Cancer

N/A

Waitlist Available

Led By Andreas Rimner, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Karnofsky performance status ≥ 70%

No prior treatment for this diagnosis of NSCLC

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing a new imaging agent, 18F-FMISO, to see if it can predict how well patients with lung cancer will respond to standard therapy, as well as if the disease will come back in the future.

Who is the study for?

This trial is for adults with NSCLC who can hold their breath for 10 seconds, have a tumor ≥2cm on CT, and are set to receive specific chemotherapy or radiation treatments. Pregnant or breastfeeding women and those with severe diabetes cannot participate.Check my eligibility

What is being tested?

Researchers are testing if the imaging agent 18F-FMISO can predict treatment response in lung cancer patients. They're also checking if mid-treatment PET scans using another agent (18F-FDG) can forecast outcomes.See study design

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort from holding breath during scanning and reactions to the imaging agents such as mild allergic responses or slight exposure to radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am able to care for myself but may not be able to do active work.

Select...

I have not received any treatment for my NSCLC diagnosis.

Select...

I am of childbearing age and my pregnancy test is negative.

Select...

My lung cancer was confirmed through testing at MSKCC.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

prognostic value of fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

progression-free survival (PFS)

Secondary outcome measures

overall survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: 18F-FMISO PET/CTExperimental Treatment2 Interventions

All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,934 Previous Clinical Trials

588,775 Total Patients Enrolled

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,551 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,612 Total Patients Enrolled

Media Library

18F-FMISO Clinical Trial Eligibility Overview. Trial Name: NCT02016872 — N/A

Non-Small Cell Lung Cancer Research Study Groups: 18F-FMISO PET/CT

Non-Small Cell Lung Cancer Clinical Trial 2023: 18F-FMISO Highlights & Side Effects. Trial Name: NCT02016872 — N/A

18F-FMISO 2023 Treatment Timeline for Medical Study. Trial Name: NCT02016872 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an ongoing recruitment process for participants in this experimental research?

"Per clinicaltrials.gov, this trial is not accepting patients at the moment due to its initial posting on December 16th 2013 and most recent update on January 3rd 2022. While no participants are being sought for this particular study, there exists a plethora of trials actively enrolling individuals."

Answered by AI

Recent research and studies

EJNMMI ResearchJournal

Reproducibility of 18f-fluoromisonidazole Intratumour Distribution in Non-small Cell Lung Cancer

Grkovski, Milan, Jazmin Schwartz, Andreas Rimner, Heiko Schöder, Sean D. Carlin, Pat B. Zanzonico, John L. Humm, and Sadek A. Nehmeh. 2016. “Reproducibility of 18f-fluoromisonidazole Intratumour Distribution in Non-small Cell Lung Cancer”. EJNMMI Research. Springer Science and Business Media LLC. doi:10.1186/s13550-016-0210-y.

clinicaltrials.govStudy

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

2013. "Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02016872.

All > Lung